RU2016116915A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016116915A3 RU2016116915A3 RU2016116915A RU2016116915A RU2016116915A3 RU 2016116915 A3 RU2016116915 A3 RU 2016116915A3 RU 2016116915 A RU2016116915 A RU 2016116915A RU 2016116915 A RU2016116915 A RU 2016116915A RU 2016116915 A3 RU2016116915 A3 RU 2016116915A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885049P | 2013-10-01 | 2013-10-01 | |
| US61/885,049 | 2013-10-01 | ||
| US201461933379P | 2014-01-30 | 2014-01-30 | |
| US61/933,379 | 2014-01-30 | ||
| PCT/IB2014/064996 WO2015049649A1 (en) | 2013-10-01 | 2014-10-01 | Combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016116915A RU2016116915A (ru) | 2017-11-13 |
| RU2016116915A3 true RU2016116915A3 (ru) | 2018-05-28 |
Family
ID=51830565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016116915A RU2016116915A (ru) | 2013-10-01 | 2014-10-01 | Комбинация |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20160228456A1 (ru) |
| EP (3) | EP4265300A3 (ru) |
| JP (3) | JP2016531884A (ru) |
| KR (1) | KR20160065910A (ru) |
| CN (3) | CN105792825A (ru) |
| AU (2) | AU2014330779A1 (ru) |
| BR (1) | BR112016006976A2 (ru) |
| CA (1) | CA2925374A1 (ru) |
| MX (1) | MX2016004267A (ru) |
| RU (1) | RU2016116915A (ru) |
| WO (1) | WO2015049649A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220047589A (ko) * | 2019-08-08 | 2022-04-18 | 래크나 리미티드 | 암 치료 방법 |
| EP4284378A1 (en) * | 2021-02-01 | 2023-12-06 | Taiho Pharmaceutical Co., Ltd. | Ptentreating cancer in patient with pten inactivating mutation |
| WO2023174210A1 (en) | 2022-03-14 | 2023-09-21 | Laekna Limited | Combination treatment for cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| ATE183926T1 (de) * | 1993-09-29 | 1999-09-15 | Alza Corp | Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| DE19918106A1 (de) | 1999-04-22 | 2000-10-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern |
| DE10107663B4 (de) | 2001-02-19 | 2004-09-09 | Lts Lohmann Therapie-Systeme Ag | Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| CA2661422C (en) * | 2006-08-25 | 2017-06-27 | Cougar Biotechnology, Inc. | Methods and compositions for treating cancer |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| AU2008309383B2 (en) * | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
| US20110288142A1 (en) * | 2009-01-30 | 2011-11-24 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| CA2765983C (en) * | 2009-06-26 | 2017-11-14 | Novartis Ag | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| JP5586888B2 (ja) * | 2009-07-23 | 2014-09-10 | 帝國製薬株式会社 | 非含水貼付製剤 |
| JP5222916B2 (ja) * | 2010-09-17 | 2013-06-26 | シャープ株式会社 | 半導体基材の製造方法、半導体装置、および電気機器 |
| WO2012097021A1 (en) * | 2011-01-11 | 2012-07-19 | Glaxosmithkline Llc | Combination |
| CN103857395A (zh) * | 2011-04-01 | 2014-06-11 | 基因泰克公司 | Akt抑制剂化合物和阿比特龙的组合及使用方法 |
| AU2012321110B2 (en) * | 2011-11-30 | 2014-10-23 | Astrazeneca Ab | Combination treatment |
| CN103301093B (zh) | 2013-06-03 | 2015-10-21 | 华润紫竹药业有限公司 | 睾酮透皮吸收贴剂 |
-
2014
- 2014-10-01 RU RU2016116915A patent/RU2016116915A/ru not_active Application Discontinuation
- 2014-10-01 AU AU2014330779A patent/AU2014330779A1/en not_active Abandoned
- 2014-10-01 BR BR112016006976A patent/BR112016006976A2/pt not_active IP Right Cessation
- 2014-10-01 US US15/024,221 patent/US20160228456A1/en not_active Abandoned
- 2014-10-01 KR KR1020167011077A patent/KR20160065910A/ko not_active Application Discontinuation
- 2014-10-01 CA CA2925374A patent/CA2925374A1/en not_active Abandoned
- 2014-10-01 EP EP23175752.7A patent/EP4265300A3/en active Pending
- 2014-10-01 CN CN201480065758.1A patent/CN105792825A/zh active Pending
- 2014-10-01 JP JP2016519395A patent/JP2016531884A/ja not_active Withdrawn
- 2014-10-01 EP EP14790343.9A patent/EP3052097A1/en not_active Ceased
- 2014-10-01 MX MX2016004267A patent/MX2016004267A/es unknown
- 2014-10-01 WO PCT/IB2014/064996 patent/WO2015049649A1/en active Application Filing
- 2014-10-01 EP EP20160587.0A patent/EP3718544A1/en not_active Withdrawn
- 2014-10-01 CN CN201910052476.2A patent/CN109674801A/zh active Pending
- 2014-10-01 CN CN201910052736.6A patent/CN109806266A/zh active Pending
-
2017
- 2017-03-28 US US15/471,614 patent/US20170239274A1/en not_active Abandoned
- 2017-09-15 AU AU2017228673A patent/AU2017228673A1/en not_active Abandoned
-
2018
- 2018-05-21 US US15/985,106 patent/US20180264008A1/en not_active Abandoned
-
2019
- 2019-07-31 JP JP2019141526A patent/JP6907273B2/ja active Active
- 2019-10-22 US US16/659,943 patent/US20200222431A1/en not_active Abandoned
-
2021
- 2021-06-30 JP JP2021108427A patent/JP7235807B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014330779A1 (en) | 2016-04-07 |
| EP3052097A1 (en) | 2016-08-10 |
| US20180264008A1 (en) | 2018-09-20 |
| JP6907273B2 (ja) | 2021-07-21 |
| US20160228456A1 (en) | 2016-08-11 |
| US20200222431A1 (en) | 2020-07-16 |
| AU2017228673A1 (en) | 2017-10-05 |
| JP2019218357A (ja) | 2019-12-26 |
| KR20160065910A (ko) | 2016-06-09 |
| US20170239274A1 (en) | 2017-08-24 |
| EP4265300A3 (en) | 2023-11-29 |
| JP2016531884A (ja) | 2016-10-13 |
| MX2016004267A (es) | 2016-07-08 |
| CN105792825A (zh) | 2016-07-20 |
| BR112016006976A2 (pt) | 2017-08-01 |
| WO2015049649A1 (en) | 2015-04-09 |
| EP3718544A1 (en) | 2020-10-07 |
| EP4265300A2 (en) | 2023-10-25 |
| CN109806266A (zh) | 2019-05-28 |
| CN109674801A (zh) | 2019-04-26 |
| RU2016116915A (ru) | 2017-11-13 |
| CA2925374A1 (en) | 2015-04-09 |
| JP2021155446A (ja) | 2021-10-07 |
| JP7235807B2 (ja) | 2023-03-08 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180918 |